Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., established in 1993 and headquartered in Victoria, British Columbia, Canada, is a key player in the biopharmaceutical sector. The company specializes in the creation and commercialization of treatments for diseases with high unmet medical needs, focusing on autoimmune diseases like lupus nephritis. Aurinia Pharmaceuticals has introduced LUPKYNIS™ (voclosporin) as its flagship brand, a prescription medication for adults with active lupus nephritis. With a strong market presence in the United States, particularly following LUPKYNIS's FDA approval in early 2021, Aurinia aims to increase its international footprint, pending regulatory sanctions and strategic commercial endeavors. (Powered by AI)